A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Exemestane (Primary) ; Tamoxifen (Primary) ; Goserelin; Triptorelin
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms SOFT
- 07 Sep 2024 This trial has been completed in Hungary, as per Eudra record.
- 06 Jun 2023 Secondary analysis evaluating the prognostic and predictive ability of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 15 Dec 2022 Results (n=4690) assessing the 12-year SOFT-TEXT late treatment effects on distant recurrence-free interval and overall survival and benefits in women with human epidermal growth factor receptor 2 negative tumors and in those at high risk of disease relapse, published in the Journal of Clinical Oncology.